1. World Health Organization. Pneumococcal conjugate
vaccine for childhood immunization—WHO position papers. Wkly
Epidemiol Record. 2007;82:93-104.
2. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal
serogroups cause the most invasive disease: implications for conjugate
vaccine formulation and use. Clin Infect Dis. 2000;30(1
Pt 1):100-121.
3. Centers for Disease Control and Prevention. Preventing pneumococcal
disease among infants and young children: Recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR. 2000;49:1-35.
4. Gray BM, Turner ME, Dillon HCJ. Epidemiologic studies of
Streptococcus
pneumoniae in infants; the effects of season and age on
pneumococcal acquisition and carriage in the first 24 months of
life.
Am J Epidemiol. 1982;116:692-703.
[PubMed: 7137156]
5. Syrjanen RK, Auranen KJ, Leino TM, Kilpi TM, Helena MP. Pneumococcal
acute otitis media in relation to pneumococcal nasopharyngeal carriage.
Pediatr
Infect Dis J. 2005;24:801-806.
[PubMed: 16148847]
6. Dowling JN, Sheehe PR, Feldman HA. Pharyngeal pneumococcal
acquisitions in “normal” families: a longitudinal
study.
J Infect Dis. 1971;124:9-17.
[PubMed: 4401272]
7. Hendley JO, Sande MA, Stewart PM, Gwaltney JMJ. Spread of
Streptococcus
pneumoniae in families. I. Carriage rates and distribution
of types.
J Infect Dis. 1975;132:55-61.
[PubMed: 1097544]
8. Whitney CG, Farley MM, Hadler J, et al. Increasing Prevalence
of multidrug-resistant Streptococcus pneumoniae in
the United States. N Engl J Med. 2000;343(26):1917-1924.
9. Black SB, Shinefield HR, Fireman B, et al. Efficacy, safety
and immunogenicity of heptavalent pneumococcal conjugate vaccine
in children.
Pediatr Infect Dis J. 2000;19:187-195.
[PubMed: 10749457]
10. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal
conjugate vaccine against acute otitis media. N Engl J Med. 2001;344(6):403-409.
11. Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent
pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus
pneumoniae in the first 2 years of life. Clin Infect
Dis. 2004;39(7):930-938.
12. Hennessy TW, Singleton RJ, Bulkow LR, et al. Impact of heptavalent
pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance
and colonization in Alaska Natives: progress towards elimination
of a health disparity. Vaccine. 2005;23(48-49):5464-5473.
13. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann
D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal
serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatr. 2005;116(3):e408-413.
14. Millar EV, O’Brien KL, Watt JP, et al. Effect of community-wide
conjugate pneumococcal vaccine use in infancy on nasopharyngeal
carriage through 3 years of age: a cross-sectional study in a high-risk
population.
Clin Infect Dis. 2006; 43(1):8-15.
[PubMed: 16758412]
15. Moore MR, Hyde TB, Hennessy TW, et al. Impact of a Conjugate
vaccine on community-wide carriage of nonsusceptible Streptococcus
pneumoniae in Alaska. J Infect Dis. 2004;190(11):2031-2038.
16. O’Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal
conjugate vaccine on nasopharyngeal colonization among immunized
and unimmunized children in a community-randomized trial. J
Infect Dis. 2007;196(8):1211-1220.
17. Centers for Disease Control and Prevention. Invasive pneumococcal
disease in children 5 years after conjugate vaccine introduction—eight
states, 1998-2005. MMWR. 2008;57:144-148.
18. Haber M, Barskey A, Baughman W, et al. Herd immunity and
pneumococcal conjugate vaccine: a quantitative model. Vaccine. 2007;25(29):5390-5398.
19. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive
pneumococcal disease after the introduction of protein-polysaccharide
conjugate vaccine. N Engl J Med. 2003;348(18):1737-1746.
20. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology
of invasive pneumococcal disease among older adults in the era of
pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16): 2043-2051.
21. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal
disease caused by nonvaccine serotypes among Alaska native children with
high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297(16):1784-1792.
22. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal
disease among infants before and after introduction of pneumococcal conjugate
vaccine. JAMA. 2006;295(14):1668-1674.
23. Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal
conjugate vaccine immunization in two Boston communities. Changes in
serotypes and antimicrobial susceptibility among
Streptococcus
pneumoniae isolates.
Pediatr Infect Dis J. 2004;23:1015-1022.
[PubMed: 15545856]
24. Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia
JJ, Pallares R. Emergence of invasive pneumococcal disease caused
by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin
Infect Dis. 2008;46(2):174-182.
25. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal
disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes
in the United States during the era of widespread PCV7 vaccination,
1998–2004. J Infect Dis. 2007;196(9):1346-1354.
26. Gonzalez BE, Hulten KG, Lamberth L, Kaplan SL, Mason EOJ,
U.S. Pediatric Multicenter Pneumococcal Surveillance Group.
Streptococcus
pneumoniae serogroups 15 and 33: an increasing cause of
pneumococcal infections in children in the United States after the
introduction of the pneumococcal 7-valent conjugate vaccine.
Pediatr
Infect Dis J. 2006;25:301-305.
[PubMed: 16567980]
27. Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends
of invasive disease due to Streptococcus pneumoniae among
children in the intermountain west: emergence of nonvaccine serogroups. Clin
Infect Dis. 2005;41(1):21-29.
28. Pichichero ME, Casey JR. Emergence of a Multiresistant serotype
19A pneumococcal strain not included in the 7-valent conjugate vaccine
as an otopathogen in children. JAMA. 2007;298(15): 1772-1778.
29. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A
as virulent and multidrug resistant pneumococcus in Massachusetts
following universal immunization of infants with pneumococcal conjugate
vaccine.
Pediatr Infect Dis J. 2007;26:468-472.
[PubMed: 17529860]
30. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction
of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N
Engl J Med. 2006;354(14):1455-1463.
31. Talbot TR, Poehling KA, Hartert TV, et al. Reduction in
high rates of antibiotic-nonsusceptible invasive pneumococcal disease
in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin
Infect Dis. 2004;39(5):641-648.
32. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial
resistance among nonvaccine serotypes of
Streptococcus pneumoniae in
the pediatric population after the introduction of 7-valent pneumococcal
vaccine in the United States.
Pediatr Infect Dis J. 2007;26:123-128.
[PubMed: 17259873]
33. Klugman KP. Editorial commentary: vaccination: a novel approach
to reduce antibiotic resistance. Clin Infect Dis. 2004;39(5):649-651.
34. Cohen R, Levy C, Rocque FdL, et al. Impact of pneumococcal
conjugate vaccine and of reduction of antibiotic use on nasopharyngeal
carriage of nonsusceptible pneumococci in children with acute otitis
media.
Pediatr Infect Dis J. 2006;25:1001-1007.
[PubMed: 17072121]
35. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus
pneumoniae virulence factors in host respiratory colonization and
disease. Nature Rev Microbiol. 2008;6(4):288-301.
36. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal
infection. N Engl J Med. 1995;332(19):1280-1284.
37. Madhi SA, Ludewick H, Kuwanda L, et al. Pneumococcal coinfection
with human metapneumovirus. J Infect Dis. 2006;193(9):1236-1243.
38. Watson M, Gilmour R, Menzies R, Ferson M, McIntyre P. The
association of respiratory viruses, temperature, and other climatic
parameters with the incidence of invasive pneumococcal disease in
Sydney, Australia. Clin Infect Dis. 2006;42(2):211-215.
39. Cherian T, Steinhoff MC, Harrison LH, Rohn D, McDougal L
K, Dick J. A cluster of invasive pneumococcal disease in young children
in child care.
JAMA. 1994;271:695-697.
[PubMed: 8309033]
40. Levine OS, Farley M, Harrison LH, et al. Risk factors for
invasive pneumococcal disease in children: a population-based case-control
study in North America. Pediatr. 1999;103(3):e28.
41. Haddad MB, Porucznik CA, Joyce KE, et al. Risk factors for
pediatric invasive pneumococcal disease in the intermountain west,
1996-2002. Ann Epidemiol. 2008;18(2):139-146.
42. Flannery B, Schrag S, Bennett NM, et al. Impact of childhood
vaccination on racial disparities in invasive Streptococcus
pneumoniae infections. JAMA. 2004;291(18):2197-2203.
43. Talbot TR, Poehling KA, Hartert TV, et al. Elimination of
racial differences in invasive pneumococcal disease in young children
after introduction of the conjugate pneumococcal vaccine.
Pediatr
Infect Dis J. 2004;23:726-731.
[PubMed: 15295222]
44. King MD, Whitney CG, Parekh F, Farley M. Recurrent invasive
pneumococcal disease: a population-based assessment. Clin
Infect Dis. 2003;37(8):1029-1036.
45. Schutze GE, Mason EO Jr, Barson WJ, et al. Invasive pneumococcal
infections in children with asplenia. Pediatr Infect Dis
J. 2002;21:287-282.
46. Adamkiewicz T, Sarnaik S, Buchanan G, et al. Invasive pneumococcal
infections in children with sickle cell disease in the era of penicillin prophylaxis,
antibiotic resistance, and 23-valent pneumococcal polysaccharide
vaccination. J Pediatr. 2003;143(4):438-444.
47. Currie A, Davidson D, Reid G, et al. Primary immunodeficiency
to pneumococcal infection due to a defect in Toll-like receptor
signaling. J Pediatr. 2004;144(4):512-518.
48. Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections
in humans with IRAK-4 deficiency. Science. 2003;299(5615):2076-2079.
49. Carrol ED, Gennery AR, Flood TJ, Spickett GP, Abinun M.
Anhidrotic ectodermal dysplasia and immunodeficiency: the role of
NEMO. Arch Dis Child. 2003;88(4):340-341.
50. Talbot TR, Hartert TV, Mitchel E, et al. Asthma as a risk
factor for invasive pneumococcal disease. N Engl J Med. 2005;352(20):2082-2090.
51. Reefhuis J, Honein MA, Whitney CG, et al. Risk of bacterial
meningitis in children with cochlear implants. N Engl J
Med. 2003;349(5):435-445.
52. Biernath KR, Reefhuis J, Whitney CG, et al. Bacterial meningitis
among children with cochlear implants beyond 24 months after implantation. Pediatr. 2006;117(2):284-289.
53. Alpern ER, Alessandrini EA, Bell LM, Shaw KN, McGowan KL.
Occult bacteremia from a pediatric emergency department: current
prevalence, time to detection, and outcome. Pediatr. 2000;106(3):505-511.
54. Benito-Fernandez J, Raso SM, Pocheville-Gurutzeta I, SanchezEtxaniz
J, Azcunaga-Santibanez B, Capape-Zache S. Pneumococcal bacteremia
among infants with fever without known source before and after introduction
of pneumococcal conjugate vaccine in the Basque Country of Spain.
Pediatr
Infect Dis J. 2007;26:667-671.
[PubMed: 17848875]
55. Herz AM, Greenhow TL, Alcantara J, et al. Changing epidemiology
of outpatient bacteremia in 3- to 36-month-old children after the
introduction of the heptavalent-conjugated pneumococcal vaccine. Pediatr
Infect Dis J. 2006;24:293-300.
56. Yamazaki T, Murayama K, Ito A, Uehara S, Sasaki N. Epidemiology
of community-acquired pneumonia in children.
Pediatr. 2005;115(2):517.
[PubMed: 15687473]
57. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards
KM, Griffin RG. Decline in pneumonia admissions after routine childhood immunisation
with pneumococcal conjugate vaccine in the USA: a time-series analysis.
Lancet. 2007;369:1179-1186.
[PubMed: 17416262]
58. Poehling KA, Lafleur BJ, Szilagyi PG, et al. Population-based
impact of pneumococcal conjugate vaccine in young children. Pediatr. 2004;114(3): 755-761.
59. Byington CL, Spencer LY, Johnson TA, et al. An epidemiological
investigation of a sustained high rate of pediatric parapneumonic
empyema: risk factors and microbiological associations. Clin
Infect Dis. 2002;34(4):434-440.
60. Eastham KM, Freeman R, Kearns AM, et al. Clinical features,
aetiology and outcome of empyema in children in the north east of
England. Thorax. 2004;59(6):522-525.
61. Schultz KD, Fan LL, Pinsky J, et al. The changing face of
pleural empyemas in children: epidemiology and management. Pediatr. 2004;113(6):1735-1740.
62. Tan TQ, Mason EO Jr, Wald ER, et al. Clinical characteristics
of children with complicated pneumonia caused by Streptococcus
pneumoniae. Pediatr. 2002;110(1):1-6.
63. Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe
staphylococcal sepsis in adolescents in the era of community-acquired
methicillin-resistant
Staphylococcus aureus.
Pediatr. 2005;115:642-648.
[PubMed: 15741366]
64. Ilyas M, Roy S III, Abbasi S, Leggiadro RJ, English BK,
Wyatt RJ. Serious infections due to penicillin-resistant
Streptococcus
pneumoniae in two children with nephrotic syndrome.
Pediatr
Nephrol. 1996;10(5):639.
[PubMed: 8897574]
65. Werno AM, Murdoch DR. Medical microbiology: laboratory diagnosis
of invasive pneumococcal disease. Clin Infect Dis. 2008;46(6):926-932.
66. Neuman MI, Harper MB. Evaluation of a rapid urine antigen
assay for the detection of invasive pneumococcal disease in children. Pediatr. 2003;112(6):1279-1282.
67. Low DE. Changing trends in antimicrobial resistant pneumococci:
it’s not all bad news. Clin Infect Dis. 2005;41:S228-233.
68. Klugman KP, Lonks JR. Hidden epidemic of macrolide resistant
pneumococci.
Emerging Infect Dis. 2005;11:802-807.
[PubMed: 15963272]
69. Pletz MWR, McGee L, Jorgensen J, et al. Levofloxacin-resistant
invasive Streptococcus pneumoniae in the United
States: evidence for clonal spread and the impact of conjugate pneumococcal
vaccine. Antimicrob. Agents Chemother. 2004;48(9):3491-3497.
70. van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids
for acute bacterial meningitis. The Cochrane Library. 2008;2.
71. Mongelluzzo J, Mohamad Z, Ten Have TR, Shah SS. Corticosteroids
and mortality in children with bacterial meningitis. JAMA. 2008;299(17):2048-2055.
72. McIntyre PB, Berkey CS, King SM, et al.
Dexamethasone as
adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical
trials since 1988.
JAMA. 1997;278:925-931.
[PubMed: 9302246]
73. Silverstein M, Bachur R, Harper MB. Clinical implications
of penicillin and ceftriaxone resistance among children with pneumococcal
bacteremia.
Pediatr Infect Dis J. 1999;18:35-41.
[PubMed: 9951978]
74. Tan TQ, Mason EO Jr, Barson WJ, et al. Clinical characteristics
and outcome of children with pneumonia attributable to penicillin-susceptible and
penicillin-nonsusceptible Streptococcus pneumoniae.Pediatr. 1998;102(6):1369-1375.
75. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance
to
levofloxacin and failure of treatment of pneumococcal pneumonia.
N
Engl J Med. 2002;346(10):747-750.
76. Daneman N, McGeer A, Green K, Low DE. Macrolide resistance
in bacteremic pneumococcal disease: implications for patient management. Clin
Infect Dis. 2006;43(4):432-438.
77. Kaplan SL, Patterson L, Edwards KM, et al. Linezolid for
the treatment of community-acquired pneumonia in hospitalized children.
Pediatr
Infect Dis J. 2001;20:488-494.
[PubMed: 11368105]
78. Subcommittee on Management of Acute Otitis Media. Diagnosis
and management of acute otitis media. Pediatr. 2004;113(5):1451-1465.
79. Garbutt J, Rosenbloom I, Wu J, Storch GA. Empiric first-line
antibiotic treatment of acute otitis in the era of the heptavalent
pneumococcal conjugate vaccine. Pediatr. 2006;117(6):e1087-1094.
80. Bedford H, de Louvois J, Halket S, Peckham C, Hurley R,
Harvey D. Meningitis in infancy in England and Wales: follow up
at age 5 years. BMJ. 2001;323(7312):533-536.
81. Arditi M, Mason Jr EO, Bradley JS, et al. Three-year multicenter
surveillance of pneumococcal meningitis in children: clinical characteristics,
and outcome related to penicillin susceptibility and
dexamethasone
use.
Pediatr. 1998;102(5):1087-1097.
82. Buckingham SC, McCullers JA, Lujan-Zilbermann J, Knapp KM,
Orman KL, English BK. Early
vancomycin therapy and adverse outcomes
in children with pneumococcal meningitis.
Pediatr. 2006;117(5):1688-1694.
83. Kaplan SL, Mason EO Jr., Wald ER, et al. Pneumococcal mastoiditis
in children. Pediatr. 2000;106 (4):695-699.
84. Nussinovitch M, Yoeli R, Elishkevitz K, Varsano I. Acute
mastoiditis in children: epidemiologic, clinical, microbiologic,
and therapeutic aspects over past years. Clin Pediatr. 2004;43:267-267.
85. Waters AM, Kerecuk L, Luk D, et al. Hemolytic uremic syndrome
associated with invasive pneumococcal disease: the United Kingdom experience. J
Pediatr. 2007;151(2):140-144.
86. Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity,
efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine. 2007;25(12):2194-2212.
87. Dagan R, Kayhty H, Wuorimaa T, et al. Tolerability and immunogenicity
of an eleven valent mixed carrier
Streptococcus pneumoniae capsular
polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine
in Finnish and Israeli infants.
Pediatr Infect Dis J. 2004;23:91-98.
[PubMed: 14872172]
88.Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent
pneumococcal conjugate vaccine in children with and those without
HIV infection. N Engl J Med. 2003;349(14):1341-1348.